Stock info AB Science | Filter  Basic-Info

AB Science

The core activities of AB Science are in the biotech sector. The past 10 years the (international) industry gained at around 59 percent. As from 2011 the sector is 70 percent higher and over the past 12 months (December 2015-December 2016) there is a minus of 59 percent.

Past year was a negative year for AB Science investors

Over the past year the company' stock gained around 1 percent. The period between August 2011 and August 2016 was a profitable period for the investors. The stock rose on average 112 percent. AB Science's revenues between 2011 and 2015 were quite unstable and moved between 1,34 million euros and 2,28 million euros. AB Science's net results between 2011 and 2015 were very fluctuating and moved between -9,65 million euros and -26,72 million euros.

The French company didn't pay out any dividends (in the past 5 years).

AB Science financed with a quite low debt position

At the end of 2015 the biotech company's balance sheet was worth 32,58 million euros. Of the total balance sheet 49,84 million euros (152,98 percent) was financed by debt. The French company's price/earnings-ratio was -16. So the market valued the stock at -16 times the 2015' earnings per share. We could say that based on it's price/earnings-ratio and dividend yield the French stock can be seen as a value stock.

At the end of 2015 the biotech company's market capitalization (the number of shares times the market price) equaled around 410,39 million euros. At the end of 2015 the French company had around 34,2 million stocks listed.

All AB Science's financial reports are available here. More information about AB Science can be found it's website. .